Revolution Medicines, Inc.

Revolution Medicines, Inc.

Biotechnology • Healthcare • Redwood City, CA, United States • RVMDW (NMS)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

650 481 6801 700 Saginaw Drive, Redwood City, CA 94063, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Harbor Capital Advisors Inc. Has $1.01 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
MarketBeat • Dec 28
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Yahoo Finance • Dec 5
Revolution Medicines stock hits all-time high at 78.2 USD - Investing.com
Investing.com • Dec 3
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil - Zacks Investment Research
Zacks Investment Research • Nov 6
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold (NASDAQ:RVMD) - Seeking Alpha
Seeking Alpha • Sep 11

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Revolution Medicines, Inc. had layoffs?
No layoff events have been recorded for Revolution Medicines, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has approximately 809 employees.
What industry is Revolution Medicines, Inc. in?
Revolution Medicines, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Revolution Medicines, Inc. a publicly traded company?
Yes, Revolution Medicines, Inc. is publicly traded under the ticker symbol RVMDW on the NMS.
Where is Revolution Medicines, Inc. headquartered?
Revolution Medicines, Inc. is headquartered in Redwood City, CA, United States at 700 Saginaw Drive, Redwood City, CA 94063, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.